

1614

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: HENDERSON  
SERIAL NO.: 09/845,741  
FILED: MAY 1, 2001  
TITLE: USE OF MEDIUM CHAIN TRIGLYCERIDES  
FOR THE TREATMENT AND PREVENTION OF  
ALZHEIMER'S DISEASE AND OTHER  
DISEASES RESULTING FROM REDUCED  
NEURONAL METABOLISM

} EXAMINER:  
} ART UNIT: 1614  
} CONFIRMATION NO: 3451

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies enclosed, which may be material to examination of the above identified application.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being submitted under 37 CFR § 1.97(c). This Statement is filed after three months from the filing date of the national application, after three months from the date of entry into national stage under 37 CFR § 1.491, after the mailing of a first Office Action on the merits, or after the mailing of a first Office Action after the filing of a requested for continued examination under 37 CFR § 1.114, but before the mailing date of any of:

- (a) a final action under 37 CFR § 1.113;
- (b) a notice of allowance under 37 CFR § 1.311; or
- (c) an action that otherwise closes prosecution in the application.

Certification under 37 CFR § 1.97(e)(1)

The undersigned hereby certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent

37 CFR 1.8

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on 3/19/04

Signature:

Name: Tasha L. Cove

*Tasha L. Cove*


office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

No fee is believed to be due in this instance. However, the undersigned hereby authorizes the charging of any fees associated with this document to Deposit Account No. 19-5117.


The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,

Date: March 19, 2004

  
Darla G. Yoerg, #48,053  
Swanson & Bratschun, P.L.C.  
1745 Shea Center Drive, Suite 330  
Highlands Ranch, Colorado 80129  
Telephone: (303) 268-0066  
Facsimile: (303) 268-0065

cc: S. Orndorff  
S:\CLIENT FOLDERS\ACCERA\ACC01\IDS3.DOC



**U.S. DEPARTMENT OF  
COMMERCE PATENT  
AND TRADEMARK  
OFFICE**

List of Information Cited by Applicant

Page 1 of 1

ATTY. DOCKET NO.

ACC.01

SERIAL NO.

09/845,741

APPLICANT

HENDERSON

FILING DATE

MAY 1, 2001

GROUP

1614

**U.S. PATENT DOCUMENTS**

EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

**FOREIGN PATENT DOCUMENTS**

EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS ?
	AO						
	AP						
	AQ						
	AR						
	AS						

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	AT	COX ET AL. (1998) J OF PEDIATRICS 133(2):247-253
	AO	THAL ET AL. (1996) NEUROLOGY 47(3):705-711
	AV	KASHIWAYA ET AL. (2000) PROC NATL ACAD SCI USA 97(10):5440-5444
	AW	
	AX	
	AY	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.